Langzeitverlauf der Parkinson-Erkrankung

G. Ebersbach

doi:10.1055/s-0038-1628776

Nervenheilkunde, Table of Contents

Nervenheilkunde 2010; 29(06): 345-350
DOI: 10.1055/s-0038-1628776

Parkinson

Schattauer GmbH

Langzeitverlauf der Parkinson-Erkrankung

Long-term course of Parkinson’s disease

G. Ebersbach

¹Neurologisches Fachkrankenhaus für Bewegungsstörungen/Parkinson, Beelitz-Heilstätten

› Author Affiliations

Abstract

Zusammenfassung

Das idiopathische Parkinsonsyndrom (IPS) verläuft chronisch progredient und führt langfristig bei den meisten Betroffenen zu Behinderung, Demenz und verminderter Lebenserwartung. In neuen Langzeitstudien wurde gezeigt, dass doparesistente Symptome wie Gleichgewichtsstörungen, Dysarthrie und Dysphagie in den Spätstadien maßgeblich für die motorische Behinderung sind. Mortalität und Pflegebedürftigkeit sind eng mit dem Auftreten von Demenz und Halluzinationen assoziiert. Der wichtigste Risikofaktor für das Auftreten dieser Komplikationen ist das Alter bei Erkrankungsbeginn. Stürze, Demenz und Halluzinationen manifestieren sich bei Patienten mit frühem Krankheitsbeginn erst nach deutlich längerem Verlauf als bei spätem Beginn des IPS. Weitere verlaufsrelevante Faktoren sind kognitive Störungen, motorischer Subtyp des IPS, Pharmakoresponsivität und genetische Disposition. Ob initial eine Behandlung mit L-Dopa oder Dopaminagonisten erfolgte war in Studien mit mehr als zehnjähriger Beobachtungsdauer für die langfristige Prognose von untergeordneter Bedeutung.

Summary

Idiopathic Parkinson’s disease (IPD) has a chronic progressive course. Late stage IPD is associated with disability, dementia and increased mortality. Recent studies with longterm follow-up have shown that disability is strongly determined by levodopa-resistant symptoms such as imbalance, dysarthria and dysphagia. Mortality and residential care are associated with dementia and hallucinations. The most important risk-factor for late-stage complications is age at disease onset. Falls, dementia and hallucinations manifest after much longer disease-duration in patients with earlier onset of disease. Further factors, including cognitive disturbances, motor subtype, response to dopaminergic medication and genetic disposition have been found to influence the course of IPD. Initiating pharmacotherapy with levodopa or dopamine agonists had little impact on long-term outcome in studies with follow-up over more than ten years.

Schlüsselwörter

Parkinson - Verlauf - Langzeitkomplikationen

Keywords

Parkinson - disease course - long-term complications

Full Text

References

Literatur
1 Aarsland D. et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387-392.
2 Aarsland D. et al. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-1126.
3 Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-942.
4 Aarsland D, Londos E, Ballard C. Parkinson’s disease dementia and dementia with Lewy bodies: different aspects of one entity. Int Psychogeriatr 2009; 21: 216-219.
5 Alves G. et al. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 2006; 21: 1123-1130.
6 Alves G. et al. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 2005; 65: 1436-1441.
7 Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson’s disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005; 112: 201-207.
8 Burn DJ. et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 2003; 18: 884-889.
9 Deuschl G. Differential diagnosis of tremor. J Neural Transm Suppl 1999; 56: 211-220.
10 Diederich NJ. et al. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003; 60: 529-533.
11 Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009; 72: 432-438.
12 Durif F. et al. Relationship between levodopa-independent symptoms and central atrophy evaluated by magnetic resonance imaging in Parkinson’s disease. Eur Neurol 1992; 32: 32-36.
13 Durso R. et al. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry 1993; 56: 65-68.
14 Ebersbach G. et al. Gleichgewichtsstörungen bei idiopathischer Parkinson-Erkrankung: Der Einfluss zerebrovaskulärer Komorbiditäten. Nervenarzt 2002; 73: 162-165.
15 El SA. et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002; 72: 31-36.
16 Emre M. et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689-1707.
17 Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 1988; 38: 1402-1406.
18 Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 2005; 20: 523-539.
19 Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 1993; 43: 2227-2229.
20 Grosset D. et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007; 78: 465-469.
21 Haugarvoll K. et al. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson’s disease. Acta Neurol Scand 2005; 112: 386-390.
22 Hauser RA. et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-17.
23 Healy DG. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 2008; 07: 583-590.
24 Hely MA. et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-9.
25 Hely MA. et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
26 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
27 Holloway RG. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-53.
28 Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-5.
29 Jobges M. et al. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1682-7.
30 Josephs KA, Matsumoto JY, Ahlskog JE. Benign tremulous parkinsonism. Arch Neurol 2006; 63: 354-57.
31 Katzenschlager R. et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
32 Kempster PA. et al. Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 2007; 130: 2123-8.
33 Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to “PARK” genes and beyond. Mov Disord 2009; 24: 2042-2058.
34 Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007; 64: 1242-1246.
35 Levy G. et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000; 55: 539-544.
36 Lippa CF. et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
37 Lo RY. et al. Clinical features in early Parkinson disease and survival. Arch Neurol 2009; 66: 1353-1358.
38 Lohmann E. et al. How much phenotypic variation can be attributed to parkin genotype?. Ann Neurol 2003; 54: 176-185.
39 Maetzler W, Liepelt I, Berg D. Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 2009; 08: 1158-1171.
40 Mayeux R. et al. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49: 492-497.
41 McKeith IG. et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
42 Muller J. et al. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55: 888-891.
43 Olanow CW. et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009; 361: 1268-1278.
44 Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain 2000; 123 (Pt 9): 1767-1783.
45 Parashos SA. et al. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc 2002; 77: 918-925.
46 Parkinson Study Group. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563-570.
47 Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 1991; 50: 743-755.
48 Paviour DC, Surtees RA, Lees AJ. Diagnostic considerations in juvenile parkinsonism. Mov Disord 2004; 19: 123-135.
49 Piccini P. et al. White matter hyperintensities in Parkinson’s disease. Clinical correlations. Arch Neurol 1995; 52: 191-194.
50 Rajput AH. et al. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009; 73: 206-212.
51 Schrag A. et al. Young-onset Parkinson’s disease revisited--clinical features, natural history, and mortality. Mov Disord 1998; 13: 885-894.
52 Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease?. J Neurol Neurosurg Psychiatry 2000; 69: 308-12.
53 Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000; 123 (Pt 11): 2297-2305.
54 Suchowersky O. et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 968-975.
55 Teravainen H. et al. The age of onset of Parkinson’s disease: etiological implications. Can J Neurol Sci 1986; 13: 317-319.
56 Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 2005; 04: 605-610.
57 Williams DR, Watt HC, Lees AJ. Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study. J Neurol Neurosurg Psychiatry 2006; 77: 468-473.
58 Williams-Gray CH. et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 2007; 130: 1787-1798.